DexCom, Inc. (NASDAQ:DXCM) Upgraded to “Hold” at ValuEngine

ValuEngine upgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a sell rating to a hold rating in a research note released on Monday, November 6th.

Several other equities research analysts have also issued reports on the stock. Morgan Stanley lowered their target price on shares of DexCom from $72.00 to $52.00 and set a neutral rating on the stock in a research note on Friday, November 3rd. Barclays PLC lowered their target price on shares of DexCom from $60.00 to $57.00 and set an equal weight rating on the stock in a research note on Thursday, November 2nd. Northland Securities reissued a hold rating and set a $50.00 target price on shares of DexCom in a research note on Thursday, November 2nd. TheStreet lowered shares of DexCom from a c- rating to a d+ rating in a research note on Wednesday, October 25th. Finally, Zacks Investment Research lowered shares of DexCom from a hold rating to a sell rating in a research note on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $70.69.

DexCom (NASDAQ:DXCM) traded up $0.20 during trading hours on Monday, reaching $55.55. 626,534 shares of the company’s stock traded hands, compared to its average volume of 1,540,744. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a one year low of $42.62 and a one year high of $88.80.

In other news, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $72.27, for a total transaction of $234,443.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The disclosure for this sale can be found here. Insiders have sold a total of 27,329 shares of company stock valued at $1,648,729 in the last 90 days. Insiders own 1.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of DXCM. Advisor Group Inc. increased its holdings in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares during the last quarter. Zions Bancorporation increased its holdings in DexCom by 36,222.2% in the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares during the last quarter. IFP Advisors Inc increased its holdings in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 568 shares during the last quarter. Toronto Dominion Bank increased its holdings in DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 2,608 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. boosted its position in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the period.

TRADEMARK VIOLATION WARNING: “DexCom, Inc. (NASDAQ:DXCM) Upgraded to “Hold” at ValuEngine” was reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://baseballnewssource.com/markets/valuengine-upgrades-dexcom-inc-dxcm-to-hold/1762541.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.